Sonnet Pretax Profit Margin vs Gross Profit Margin Analysis

SONN Stock

USD 1.75 0.15 9.37%

Sonnet Biotherapeutics financial indicator trend analysis is much more than just breaking down Sonnet Biotherapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sonnet Biotherapeutics is a good investment. Please check the relationship between Sonnet Biotherapeutics Pretax Profit Margin and its Gross Profit Margin accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Pretax Profit Margin vs Gross Profit Margin

Pretax Profit Margin vs Gross Profit Margin Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sonnet Biotherapeutics Pretax Profit Margin account and Gross Profit Margin. At this time, the significance of the direction appears to have very week relationship.

The correlation between Sonnet Biotherapeutics' Pretax Profit Margin and Gross Profit Margin is 0.21. Overlapping area represents the amount of variation of Pretax Profit Margin that can explain the historical movement of Gross Profit Margin in the same time period over historical financial statements of Sonnet Biotherapeutics Holdings, assuming nothing else is changed. The correlation between historical values of Sonnet Biotherapeutics' Pretax Profit Margin and Gross Profit Margin is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Pretax Profit Margin of Sonnet Biotherapeutics Holdings are associated (or correlated) with its Gross Profit Margin. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Gross Profit Margin has no effect on the direction of Pretax Profit Margin i.e., Sonnet Biotherapeutics' Pretax Profit Margin and Gross Profit Margin go up and down completely randomly.

Correlation Coefficient

0.21

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Pretax Profit Margin

Gross Profit Margin

Most indicators from Sonnet Biotherapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sonnet Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

As of the 5th of January 2025, Tax Provision is likely to grow to about 69.7 K, while Selling General Administrative is likely to drop about 2.4 M.

	2024	2025 (projected)
Non Recurring	10.9M	11.5M
Cost Of Revenue	7.1M	11.8M

Non Recurring Cost Of Revenue

Sonnet Biotherapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Accounts Payable	Non Current Assets Total	Other Assets	Net Receivables	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Retained Earnings	Cash	Non Currrent Assets Other	Cash And Short Term Investments	Other Current Assets	Other Current Liab	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding
Total Assets		0.82	0.88	0.83	0.72	0.04	0.28	0.46	0.73	-0.16	0.25	0.59	0.03	0.89	0.18	0.68	-0.33	0.05	0.15	-0.09	0.15	-0.23	-0.24	0.53	0.36	-0.63
Short Long Term Debt Total	0.82		0.9	0.42	0.82	0.25	0.71	0.2	0.85	-0.12	0.03	0.8	-0.03	0.95	-0.3	0.89	-0.18	0.05	-0.3	-0.12	-0.3	-0.46	-0.22	0.46	0.19	-0.52
Total Current Liabilities	0.88	0.9		0.54	0.75	0.12	0.49	0.38	0.76	-0.06	0.41	0.64	0.24	0.96	-0.03	0.8	-0.25	-0.19	-0.07	-0.25	-0.07	-0.1	-0.37	0.67	0.34	-0.68
Total Stockholder Equity	0.83	0.42	0.54		0.43	-0.15	-0.16	0.41	0.4	-0.21	0.28	0.18	0.0	0.49	0.51	0.39	-0.34	0.17	0.5	-0.07	0.5	-0.12	-0.09	0.24	0.41	-0.42
Property Plant And Equipment Net	0.72	0.82	0.75	0.43		0.25	0.65	0.33	0.98	-0.44	0.09	0.84	-0.25	0.79	-0.34	0.7	0.24	0.28	-0.35	0.02	-0.35	-0.5	-0.26	0.49	0.44	-0.6
Current Deferred Revenue	0.04	0.25	0.12	-0.15	0.25		0.15	-0.26	0.26	0.41	-0.04	0.54	0.25	0.22	-0.06	0.28	0.39	-0.26	-0.03	0.25	-0.03	-0.16	-0.21	0.33	-0.12	-0.41
Net Debt	0.28	0.71	0.49	-0.16	0.65	0.15		0.01	0.67	-0.24	-0.29	0.62	-0.2	0.59	-0.88	0.63	-0.02	0.13	-0.88	-0.01	-0.88	-0.54	-0.02	0.12	0.08	-0.12
Accounts Payable	0.46	0.2	0.38	0.41	0.33	-0.26	0.01		0.32	-0.4	0.28	0.12	-0.02	0.34	0.15	0.04	-0.16	0.01	0.1	-0.06	0.1	0.21	-0.39	0.34	0.31	-0.24
Non Current Assets Total	0.73	0.85	0.76	0.4	0.98	0.26	0.67	0.32		-0.44	0.02	0.89	-0.25	0.82	-0.37	0.69	0.23	0.27	-0.37	-0.06	-0.37	-0.52	-0.26	0.52	0.33	-0.64
Other Assets	-0.16	-0.12	-0.06	-0.21	-0.44	0.41	-0.24	-0.4	-0.44		0.23	-0.13	0.61	-0.04	0.27	-0.02	-0.29	-0.63	0.27	0.22	0.27	0.34	0.26	0.1	-0.22	0.04
Net Receivables	0.25	0.03	0.41	0.28	0.09	-0.04	-0.29	0.28	0.02	0.23		-0.1	0.6	0.21	0.49	0.15	-0.05	-0.52	0.42	-0.2	0.42	0.51	-0.4	0.6	0.53	-0.42
Non Current Liabilities Total	0.59	0.8	0.64	0.18	0.84	0.54	0.62	0.12	0.89	-0.13	-0.1		-0.2	0.78	-0.36	0.64	0.29	0.16	-0.34	0.13	-0.34	-0.52	-0.24	0.51	0.06	-0.64
Other Stockholder Equity	0.03	-0.03	0.24	0.0	-0.25	0.25	-0.2	-0.02	-0.25	0.61	0.6	-0.2		0.11	0.35	0.09	-0.29	-0.96	0.28	-0.18	0.28	0.65	-0.32	0.42	-0.08	-0.11
Total Liab	0.89	0.95	0.96	0.49	0.79	0.22	0.59	0.34	0.82	-0.04	0.21	0.78	0.11		-0.15	0.81	-0.25	-0.1	-0.17	-0.09	-0.17	-0.26	-0.32	0.63	0.24	-0.66
Total Current Assets	0.18	-0.3	-0.03	0.51	-0.34	-0.06	-0.88	0.15	-0.37	0.27	0.49	-0.36	0.35	-0.15		-0.25	-0.15	-0.24	0.99	-0.09	0.99	0.5	-0.15	0.17	0.04	-0.18
Short Term Debt	0.68	0.89	0.8	0.39	0.7	0.28	0.63	0.04	0.69	-0.02	0.15	0.64	0.09	0.81	-0.25		-0.19	-0.03	-0.25	-0.18	-0.25	-0.4	-0.17	0.3	0.16	-0.42
Common Stock	-0.33	-0.18	-0.25	-0.34	0.24	0.39	-0.02	-0.16	0.23	-0.29	-0.05	0.29	-0.29	-0.25	-0.15	-0.19		0.28	-0.11	-0.01	-0.11	-0.17	-0.08	0.12	-0.01	-0.18
Retained Earnings	0.05	0.05	-0.19	0.17	0.28	-0.26	0.13	0.01	0.27	-0.63	-0.52	0.16	-0.96	-0.1	-0.24	-0.03	0.28		-0.16	0.14	-0.16	-0.66	0.31	-0.46	0.16	0.07
Cash	0.15	-0.3	-0.07	0.5	-0.35	-0.03	-0.88	0.1	-0.37	0.27	0.42	-0.34	0.28	-0.17	0.99	-0.25	-0.11	-0.16		-0.07	1.0	0.43	-0.11	0.12	0.02	-0.17
Non Currrent Assets Other	-0.09	-0.12	-0.25	-0.07	0.02	0.25	-0.01	-0.06	-0.06	0.22	-0.2	0.13	-0.18	-0.09	-0.09	-0.18	-0.01	0.14	-0.07		-0.07	-0.1	0.11	-0.26	0.1	0.16
Cash And Short Term Investments	0.15	-0.3	-0.07	0.5	-0.35	-0.03	-0.88	0.1	-0.37	0.27	0.42	-0.34	0.28	-0.17	0.99	-0.25	-0.11	-0.16	1.0	-0.07		0.43	-0.11	0.12	0.02	-0.17
Other Current Assets	-0.23	-0.46	-0.1	-0.12	-0.5	-0.16	-0.54	0.21	-0.52	0.34	0.51	-0.52	0.65	-0.26	0.5	-0.4	-0.17	-0.66	0.43	-0.1	0.43		-0.21	0.2	-0.11	0.0
Other Current Liab	-0.24	-0.22	-0.37	-0.09	-0.26	-0.21	-0.02	-0.39	-0.26	0.26	-0.4	-0.24	-0.32	-0.32	-0.15	-0.17	-0.08	0.31	-0.11	0.11	-0.11	-0.21		-0.49	-0.12	0.43
Good Will	0.53	0.46	0.67	0.24	0.49	0.33	0.12	0.34	0.52	0.1	0.6	0.51	0.42	0.63	0.17	0.3	0.12	-0.46	0.12	-0.26	0.12	0.2	-0.49		0.34	-0.79
Common Stock Total Equity	0.36	0.19	0.34	0.41	0.44	-0.12	0.08	0.31	0.33	-0.22	0.53	0.06	-0.08	0.24	0.04	0.16	-0.01	0.16	0.02	0.1	0.02	-0.11	-0.12	0.34		-0.36
Common Stock Shares Outstanding	-0.63	-0.52	-0.68	-0.42	-0.6	-0.41	-0.12	-0.24	-0.64	0.04	-0.42	-0.64	-0.11	-0.66	-0.18	-0.42	-0.18	0.07	-0.17	0.16	-0.17	0.0	0.43	-0.79	-0.36

Click cells to compare fundamentals

Sonnet Biotherapeutics Account Relationship Matchups

Sonnet Biotherapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	8.0M	29.0M	5.8M	5.4M	2.8M	28.3M
Short Long Term Debt Total	353.3K	125.9K	256.0K	203.9K	130.9K	9.8M
Total Current Liabilities	4.7M	6.7M	8.2M	5.5M	3.2M	12.4M
Total Stockholder Equity	3.0M	22.3M	(2.5M)	(226.0K)	(485.7K)	8.4M
Property Plant And Equipment Net	273.8K	182.3K	302.8K	227.1K	143.9K	10.2M
Current Deferred Revenue	500K	516.4K	166.4K	18.6K	1.1M	1.1M
Net Debt	(7.0M)	(27.5M)	(2.8M)	(2.1M)	(18.6K)	9.3M
Accounts Payable	2.1M	3.8M	4.8M	2.2M	2.2M	2.3M
Non Current Assets Total	356.8K	182.3K	416.1K	691.2K	653.1K	27.0M
Liabilities And Stockholders Equity	8.0M	29.0M	5.8M	5.4M	2.8M	28.3M
Non Current Liabilities Total	250.0K	30.6K	203.9K	130.9K	46.6K	8.1M
Other Stockholder Equity	39.7M	83.9M	88.9M	110.0M	117.2M	60.9M
Total Liab	5.0M	6.7M	8.4M	5.7M	3.3M	20.5M
Total Current Assets	7.6M	28.8M	5.4M	4.7M	2.1M	1.3M
Short Term Debt	103.2K	95.3K	52.1K	73.0K	84.3K	12.8M
Common Stock	1.5K	6.0K	554.0	175.0	65.0	354.35
Retained Earnings	(36.7M)	(61.7M)	(91.4M)	(110.2M)	(117.7M)	(60.0M)
Cash	7.3M	27.6M	3.1M	2.3M	149.5K	497.9K
Non Currrent Assets Other	83.0K	(182.3K)	113.3K	464.2K	509.1K	2.7M
Cash And Short Term Investments	7.3M	27.6M	3.1M	2.3M	149.5K	497.9K
Other Current Assets	575.5K	2.4M	4.0M	1.7M	2.0M	151.2K
Other Current Liab	2.1M	2.3M	3.2M	3.2M	942.5K	2.7M
Common Stock Shares Outstanding	30.6K	79.7K	197.5K	1.0M	655.2K	417.6
Property Plant And Equipment Gross	273.8K	182.3K	302.8K	227.1K	8.8M	5.3M
Net Tangible Assets	7.4M	3.0M	22.3M	(2.5M)	8.5M	9.0M
Capital Lease Obligations	207.2K	125.1K	255.2K	203.9K	18.4K	17.4K

When determining whether Sonnet Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonnet Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonnet Biotherapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonnet Biotherapeutics Holdings Stock:

How To Invest In Sonnet

Details

Is Sonnet Stock a good investment?

Details

What is Sonnet Biotherapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(11.35)

Revenue Per Share

0.019

Quarterly Revenue Growth

(0.50)

Return On Assets

(0.97)

Return On Equity

(2.65)

The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Sonnet Pretax Profit Margin vs Gross Profit Margin Analysis

Pretax Profit Margin vs Gross Profit Margin

Pretax Profit Margin vs Gross Profit Margin Correlation Analysis

Correlation Coefficient

Pretax Profit Margin

Gross Profit Margin

Sonnet Biotherapeutics fundamental ratios Correlations

Sonnet Biotherapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Sonnet Biotherapeutics fundamental ratios Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Cash	+ 0.99	Total Current Assets
Cash And Short Term Investments	+ 0.99	Total Current Assets
Non Current Assets Total	+ 0.98	Property Plant And Equipment Net
Total Liab	+ 0.96	Total Current Liabilities
Total Liab	+ 0.95	Short Long Term Debt Total

Retained Earnings	- 0.96	Other Stockholder Equity
Cash And Short Term Investments	- 0.88	Net Debt
Cash	- 0.88	Net Debt
Total Current Assets	- 0.88	Net Debt
Common Stock Shares Outstanding	- 0.79	Good Will
Common Stock Shares Outstanding	- 0.68	Total Current Liabilities